Yousif Capital Management LLC Has $18.95 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Yousif Capital Management LLC reduced its holdings in Danaher Co. (NYSE:DHR) by 2.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,892 shares of the conglomerate’s stock after selling 2,484 shares during the period. Yousif Capital Management LLC’s holdings in Danaher were worth $18,945,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Wellington Management Group LLP grew its position in Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares during the last quarter. Allen Investment Management LLC grew its position in Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after buying an additional 1,028,976 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in Danaher during the third quarter valued at about $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new position in Danaher in the 4th quarter valued at approximately $161,994,000. Finally, Harris Associates L P lifted its position in shares of Danaher by 27.7% in the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock worth $735,343,000 after acquiring an additional 642,759 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

DHR traded up $17.03 during trading on Tuesday, hitting $253.11. The company’s stock had a trading volume of 6,876,631 shares, compared to its average volume of 2,777,720. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $187.44 billion, a price-to-earnings ratio of 39.61, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. The firm’s 50 day moving average price is $248.95 and its two-hundred day moving average price is $230.64. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the previous year, the business posted $2.87 earnings per share. The firm’s revenue for the quarter was down 10.2% compared to the same quarter last year. Sell-side analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is 16.90%.

Insider Activity at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of the company’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 over the last quarter. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays increased their price objective on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp upped their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada raised their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $268.27.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.